Filing summary
Entity and period mismatch: The supplied filing is Zafgen, Inc.’s Form 10-K for the fiscal year ended December 31, 2017, filed March 9, 2018. It is not a filing for Larimar Therapeutics, Inc.; the filing identifies Zafgen and its Nasdaq symbol ZFGN. It reports annual results, not a standalone fourth quarter.
Business context and reporting period
Zafgen was a clinical-stage biopharmaceutical company developing MetAP2 inhibitors for metabolic diseases. Its lead candidate, ZGN-1061, was in Phase 2 development for type 2 diabetes; ZGN-1258 was in nonclinical development, with Prader-Willi syndrome (PWS) as its intended initial indication. The company had no approved products or product sales.
The 10-K covers the year ended December 31, 2017 and compares results principally with 2016. Clinical updates disclosed in the filing include information available after year-end: ZGN-1061 Phase 2 interim results announced March 6, 2018, and plans for ZGN-1258 development in 2018.
Financial and operating metrics
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $40.839 million | $39.936 million |
| General and administrative expense | $12.160 million | $18.289 million |
| Total operating expenses / operating loss | $52.999 million / $(52.999) million | $58.225 million / $(58.225) million |
| Net loss | $(52.028) million | $(57.878) million |
| Net loss per share, basic and diluted | $(1.90) | $(2.12) |
| Cash used in operating activities | $(43.784) million | $(51.975) million |
| Cash, cash equivalents and marketable securities at year-end | $102.052 million | $129.194 million |
| Working capital | $97.632 million | $121.005 million |
| Long-term notes payable at year-end | $20.000 million | $0 |
| Total assets / stockholders’ equity | $105.510 million / $78.217 million | $131.621 million / $121.727 million |
As a pre-revenue development company, conventional gross and operating margins are not meaningful. Interest income was $0.996 million in 2017; interest expense was $0.165 million. Cash provided by investing activities was $35.647 million, mainly reflecting net sales and maturities of marketable securities. Financing activities provided $16.562 million, including the $20 million term-loan proceeds, partly offset by debt repayments.
Material changes versus the prior comparable period
- Net loss narrowed by $5.850 million, while total operating expenses fell $5.226 million. The lower loss reflected reduced G&A and other expenses, partly offset by higher R&D.
- R&D increased $0.903 million. ZGN-1061 program spending rose $10.352 million and discovery and screening costs rose $5.946 million; these increases were largely offset by a $12.889 million reduction in beloranib spending after its development was suspended.
- G&A decreased $6.129 million, primarily from lower stock-based compensation, personnel costs and professional fees following the 2016 workforce reduction and reduced legal and commercial-readiness activity.
- Year-end cash, cash equivalents and marketable securities declined $27.142 million. The company raised no public-offering proceeds in 2017, but entered a new $20 million term loan in December.
Outlook, risks, contingencies and unusual items
- Runway and financing: Management expected year-end liquidity to fund operations, capital expenditures and debt repayments for at least one year from the 10-K’s issuance date. It also stated that additional financing would be required to continue development and commercialization. The auditor included an emphasis-of-matter paragraph noting the need for additional financing and referring to management’s plans.
- Debt and liquidity covenants: The $20 million Silicon Valley Bank loan carries a variable rate of prime plus 1.25% (prime was 4.5% at year-end), an 8% final payment, interest-only payments through March 2019 and scheduled principal and interest payments thereafter through December 2021. It is secured by substantially all personal property except intellectual property. Minimum liquidity requirements, cash-location provisions and restrictive covenants may constrain operations.
- Clinical development: ZGN-1061 Phase 1 results were described as generally well tolerated, with no observed pro-thrombotic signal. A Phase 2 interim analysis reported a placebo-adjusted A1C change of -0.57% at eight weeks for the 0.9 mg dose (p<0.05); a preliminary 12-week analysis reported -0.86% (p<0.005), based on small patient counts. The company added a higher-dose arm and expected core trial results mid-2018 and full results, including the added arm, early 2019. These are interim findings and not proof of later-stage safety or efficacy.
- Key development risk: The prior MetAP2 inhibitor beloranib was discontinued after serious thrombotic-event concerns and an FDA clinical hold. Zafgen emphasized that safety and efficacy findings for ZGN-1061 and ZGN-1258 remained uncertain; later trials could produce different results or identify adverse events.
- Other program plans: Zafgen planned to prepare and file an IND for ZGN-1258 and begin Phase 1 development by year-end 2018, subject to nonclinical results and regulatory review. It also expected to begin a PWS natural-history study in mid-2018 and was evaluating liver-targeted candidates.
- Operational and market risks: The company depended on third-party manufacturers and clinical research organizations, had no commercial infrastructure, and reported no long-term manufacturing supply agreements. Additional capital, successful trials, regulatory approvals, reimbursement and market acceptance were all uncertain.
- Tax and other items: The 2017 Tax Cuts and Jobs Act required remeasurement of deferred tax assets; the filing reported a $33.8 million tax-expense provision offset by a corresponding valuation-allowance reduction, with no net impact on the financial statements. A 2016 restructuring reduced the workforce by about 31%; the company said it did not expect significant further restructuring costs. A securities class action related to beloranib disclosures was dismissed with prejudice, and the dismissal was affirmed on appeal in April 2017.
Most important facts for investors to verify
- Confirm the issuer: this document is Zafgen, Inc.’s 2017 10-K, not a Larimar Therapeutics filing.
- Review the full audited statements and notes, particularly the $20 million secured loan, its liquidity covenants, repayment schedule and effective interest rate.
- Assess the company’s actual cash burn and financing needs against management’s stated minimum one-year runway; the auditor highlighted the need for additional financing.
- Check subsequent ZGN-1061 trial disclosures, including full Phase 2 results, the added-dose arm, patient counts and any coagulation or other safety findings.
- Verify whether ZGN-1258’s IND and clinical-development milestones were achieved, and whether the PWS program advanced as planned.